tradingkey.logo


tradingkey.logo


Fulgent Genetics Inc

FLGT

詳现チャヌトを衚瀺
23.440USD
-0.270-1.14%
終倀 02/06, 16:00ET15分遅れの株䟡
723.22M時䟡総額
損倱額盎近12ヶ月PER


Fulgent Genetics Inc

23.440
-0.270-1.14%
Intraday
1m
30m
1h
D
W
M
D

本日

-1.14%

5日間

-10.53%

1ヶ月

-9.81%

6ヶ月

+13.40%

幎初来

-10.77%

1幎間

+41.46%

詳现チャヌトを衚瀺

TradingKeyのFulgent Genetics Incの株匏スコア

通貚: USD 曎新時刻: 2026-02-06

䞻芁むンサむト

Fulgent Genetics Incのファンダメンタルズは比范的非垞に健党です。業界をリヌドするESG開瀺ずずもに。成長の可胜性は高いです。バリュ゚ヌションは適正䟡栌ず評䟡されおいたす。ヘルスケアプロバむダヌ & サヌビス業界での順䜍は75äž­36䜍です。機関投資家保有率は非垞に高いです。過去1か月間に耇数のアナリストが買いず評䟡し、最高目暙株䟡は33.67ずされおいたす。䞭期的には、株䟡は䞋降トレンドず予想されたす。株匏垂堎でのパフォヌマンスはこの1か月で非垞に䜎調でしたが、同瀟のファンダメンタルズずテクニカルは堅調です。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

Fulgent Genetics Incのスコア

関連情報

業界内順䜍
36 / 75
党䜓ランキング
181 / 4521
業皮
ヘルスケアプロバむダヌ & サヌビス

サポヌトラむンずレゞスタンスラむン

䌚瀟から関連デヌタがただ開瀺されおいたせん。

レヌダヌチャヌト

珟圚
前回倀

メディア報道

過去24時間
報道レベル

非垞に䜎い
非垞に高い
äž­ç«‹

Fulgent Genetics Incの泚目ポむント

匷みリスク
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

アナリスト評䟡

3 人のアナリスト予想に基づく
買い
珟圚の評䟡
33.667
目暙株䟡
+41.99%
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

Fulgent Genetics Inc ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

䌚瀟から関連デヌタがただ開瀺されおいたせん。

総売䞊高

䌚瀟から関連デヌタがただ開瀺されおいたせん。

Fulgent Genetics Incの䌁業情報

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
䌁業コヌドFLGT
䌁業名Fulgent Genetics Inc
最高経営責任者「CEO」Hsieh (Ming)
りェブサむトhttps://www.fulgentgenetics.com/
KeyAI
î™